CD274 and non-small cell lung carcinoma: This part will evaluate the efficacy and safety of MEM-288 concurrently with nivolumab in patients with advanced/metastatic NSCLC who have relapsed after initial treatment with antiPD-1/PD-L1 with or without concurrent chemotherapy.